Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide with Osimertinib or Lorlatinib for NSCLC with CNS Progression
NCT04541407Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of temozolomide in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Colorado Denver. Primary endpoint: Adverse events up to 3.5 years. Started Oct 2020; status: completed.
02
Drugs
temozolomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04541407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541407.